BCG-medac Basisdokumentation - medac GmbH

Morales A. (1984)
Long-Term Results and Complications of Intracavitary bacillus Calmette-Guérin Therapy for
Bladder Cancer
J . Urol ., 132: 457-459
Morales A., Nickel J.c., Wilson J.W.L. (1992)
Dose-response of bacillus calmette-guérin in the treatment of superficial bladder cancer
J . Urol ., 147: 1256-1258
Morton D.L., eilber F.R., Malmgren R.A. (1970)
Immunological factors which influence response to immunotherapy in malingnant melanoma
.
Surgery, 68: 158-164
Morton D.L. (1971)
Immunological studies with human neoplasms
J . Reticuloendothel Soc .; 10, 137-160
Morton D.L., Holmes e.c., eilber F.R. (1971)
Immunological aspects of neoplasia: a rational basis for immunotherapy
Ann . Intern . Med ., 74: 587-604
Neumann R.M., cheng L., cheville J.c., Leibovich B.c., Spotts B.e.,
Bostwick D.G. (1999)
Long-Term Follow-Up Of Patients With Carcinoma In Situ Of The Urinary Bladder
J . Urol ., 161 (Suppl .): A
Nieder A.M., Brausi M., Lamm D., o‘Donnell M., tomita k., Woo H., Jewett MA. (2005)
Management of stage T1 tumors of the bladder: International Consensus Panel .
Urology; 66(6 Suppl 6A):108-25
ojea A, Nogueira JL, Solsona e, Flores N, Gomez JM, Molina JR, chantada V,
camacho Je, Pineiro LM, Rodriguez RH, Isorna S, Blas M, Martinez-Pineiro JA,
Madero R; Members of the cueto Group (club Urologico espanol De tratamiento
oncologico).(2007)
A Multicentre, Randomised Prospective Trial Comparing Three Intravesical Adjuvant Therapies
for Intermediate-Risk Superficial Bladder Cancer: Low-Dose Bacillus Calmette-Guerin
(27 mg) versus Very Low-Dose Bacillus Calmette-Guerin (13 .5 mg) versus Mitomycin C .
Eur Urol .;52(5):1398-406
okamura t., tozawa k., yamada y., Sakagami H., Ueda k., kohri k. (1996)
Clinicopathological evaluation of repeated courses of intravesical Bacillus Calmette-Guérin
instillation for preventing recurrence of initially resistannt superficial bladder cancer .
J . Urol ., 156: 967-971
Pagano F., Bassi P., Milani c., Meneghini A., Maruzzi D., Garbeglio A. (1991)
A low dose bacillus calmette guérin regimen in superficial bladder cancer therapy: is it effective?
J . Urol ., 146: 32-35
Pagano F, Bassi P, Piazza N, Abatangelo G, Drago Ferrante GL, Milani c. (1995)
Improving the efficacy of BCG immunotherapy by dose reduction .
Eur Urol .;27 Suppl 1:19-22
Palou J., Sanchez-Martin F.M., Rosales A., Salvador J., et al. (1999)
Intravesical Bacillus Calmette Guérin in the treatment of carcinoma in situ or high grade
superficial bladder carcinoma after radiotherapy for bladder cancer
BJU . Int ., 83: 429-431
Pansadoro V, emiliozzi P, de Paula F, Scarpone P, Pansadoro A, Sternberg cN (2002)
Long-Term Follow-up of G3T1 Transitional Cell Carcinoma of the Bladder Treated with
Intravesical Bacille Calmette-Guérin: 18-Year Experience
Urology, 59 (2): 227-230
Papadimitriou J.M., Spector W.G. (1982)
The ultrastructure of high- and low-turnover inflammatory granulomata
J . Pathol ., 106: 37-37
69